Open Access

Clinical outcome of patients with inoperable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus Nab‑paclitaxel as a first‑line therapy: A retrospective analysis

  • Authors:
    • Hiroyuki Sakaguchi
    • Azusa Tanimoto
    • Shigeki Sato
    • Naohiro Yanagimura
    • Chiaki Suzuki
    • Yohei Takumi
    • Akihiro Nishiyama
    • Kaname Yamashita
    • Shinji Takeuchi
    • Koshiro Ohtsubo
    • Seiji Yano
  • View Affiliations

  • Published online on: July 5, 2021     https://doi.org/10.3892/mi.2021.8
  • Article Number: 8
  • Copyright : © Sakaguchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to evaluate the clinical benefits of leucovorin, 5‑fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) vs. gemcitabine plus Nab‑paclitaxel (GnP) as a first‑line therapy for patients with inoperable pancreatic cancer. For this purpose, in‑house data available for 45 patients who received FOLFIRINOX or GnP as first‑line treatment between 2014 and 2019 were retrospectively analyzed. In total, 21 and 24 patients received FOLFIRINOX and GnP, respectively. Although there were no significant differences in the median progression‑free survival, the median overall survival was longer in the FOLFIRINOX group than in the GnP group (16.7 vs. 7.2 months). A total of 14 patients received FOLFIRINOX followed by GnP, whereas 3 patients received GnP followed by FOLFIRINOX. All patients who did not switch to second‑line therapy owing to poor feasibility were included in the GnP group. The data indicated that patients receiving GnP as first‑line therapy were less likely to switch to FOLFIRINOX and, consequently, had a worse prognosis.

Related Articles

Journal Cover

September-October 2021
Volume 1 Issue 4

Print ISSN: -
Online ISSN:2754-1304

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sakaguchi H, Tanimoto A, Sato S, Yanagimura N, Suzuki C, Takumi Y, Nishiyama A, Yamashita K, Takeuchi S, Ohtsubo K, Ohtsubo K, et al: Clinical outcome of patients with inoperable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus Nab‑paclitaxel as a first‑line therapy: A retrospective analysis. Med Int 1: 8, 2021
APA
Sakaguchi, H., Tanimoto, A., Sato, S., Yanagimura, N., Suzuki, C., Takumi, Y. ... Yano, S. (2021). Clinical outcome of patients with inoperable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus Nab‑paclitaxel as a first‑line therapy: A retrospective analysis. Medicine International, 1, 8. https://doi.org/10.3892/mi.2021.8
MLA
Sakaguchi, H., Tanimoto, A., Sato, S., Yanagimura, N., Suzuki, C., Takumi, Y., Nishiyama, A., Yamashita, K., Takeuchi, S., Ohtsubo, K., Yano, S."Clinical outcome of patients with inoperable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus Nab‑paclitaxel as a first‑line therapy: A retrospective analysis". Medicine International 1.4 (2021): 8.
Chicago
Sakaguchi, H., Tanimoto, A., Sato, S., Yanagimura, N., Suzuki, C., Takumi, Y., Nishiyama, A., Yamashita, K., Takeuchi, S., Ohtsubo, K., Yano, S."Clinical outcome of patients with inoperable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus Nab‑paclitaxel as a first‑line therapy: A retrospective analysis". Medicine International 1, no. 4 (2021): 8. https://doi.org/10.3892/mi.2021.8